What is the optimal second-line antidiabetic regimen to delay the onset of microvascular complications? Application of a marginal structural model

AK Wright; Darren M Ashcroft; Martin K Rutter; Richard Emsley; DT Steinke

What is the optimal second-line antidiabetic regimen to delay the onset of microvascular complications? Application of a marginal structural model

AK Wright, Darren M Ashcroft, Martin K Rutter, Richard Emsley, DT Steinke

Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review

Original language	English
Title of host publication	host publication
Place of Publication	Pharmacoepidemiology and Drug Safety (Suppl S1)
Pages	976-976
Number of pages	1
Publication status	Published - 2015

Cite this

@inproceedings{7160eca832cc4e1d9c8c72bd6a947b4b,

title = "What is the optimal second-line antidiabetic regimen to delay the onset of microvascular complications? Application of a marginal structural model",

author = "AK Wright and Ashcroft, {Darren M} and Rutter, {Martin K} and Richard Emsley and DT Steinke",

year = "2015",

language = "English",

pages = "976--976",

booktitle = "host publication",

}

What is the optimal second-line antidiabetic regimen to delay the onset of microvascular complications? Application of a marginal structural model. / Wright, AK; Ashcroft, Darren M ; Rutter, Martin K et al.
host publication. Pharmacoepidemiology and Drug Safety (Suppl S1), 2015. p. 976-976.

Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - What is the optimal second-line antidiabetic regimen to delay the onset of microvascular complications? Application of a marginal structural model

AU - Wright, AK

AU - Ashcroft, Darren M

AU - Rutter, Martin K

AU - Emsley, Richard

AU - Steinke, DT

PY - 2015

Y1 - 2015

M3 - Conference contribution

SP - 976

EP - 976

BT - host publication

CY - Pharmacoepidemiology and Drug Safety (Suppl S1)

ER -